Effects of rituximab therapy on quality of life in patients with primary Sjögren's syndrome.
Clin Exp Rheumatol 29(1):6-12 (2011) PMID 21345287
To assess the efficacy of the anti-CD20 antibody rituximab in improving physical function and health-related quality of life (HRQoL) in patients with active primary Sjögren's syndrome (pSS), as well as the duration and sources of HRQoL improvements.
Version: za2963e q8za5 q8zb0 q8zcf q8zd2 q8ze8 q8zf7 q8zg7